Qi Wu

Qi Wu

Auto-generated profile, based on publicly available information

Qi Wu

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Endoscopy Center, Peking University Cancer Hospital & Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2023 in World Journal of Psychiatry
Verified
Journal Article
Open access
YWYu-Mei Wei
Yu-Mei Wei
XWXi-Jin Wang
Xi-Jin Wang
XYXiaodong Yang
Xiaodong Yang
CWChuan-Sheng Wang
Chuan-Sheng Wang
LWLi-Li Wang
Li-Li Wang
YSYifeng SHEN
Yifeng SHEN
BACKGROUND Schizophrenia is a psychiatric disorder characterized by chronic or recurrent symptoms. Lurasidone was licensed in China in 2019 for the treatment of adult schizophrenia in adults with a maximum dose of 80 mg/d. However, post-market surveillance (PMS) with an adequate sample size is required for further validation of the drug’s safety profile and effectiveness. AIM To conduct PMS in real-world clinical settings and evaluate the safety and effectiveness of lurasidone in the Chinese population. METHODS A prospective, multicenter, open-label, 12-wk surveillance was conducted in mainland China. All patients with schizophrenia from 10 sites who had begun medication with lurasidone between September 2019 and August 2022 were eligible for enrollment. Safety assessments included adverse events (AEs), adverse drug reactions (ADRs), extrapyramidal symptoms (EPS), akathisia, use of EPS drugs, weight gain, and laboratory values as metabolic parameters and the QTc interval. The effectiveness was assessed using the brief psychiatric rating scale (BPRS) from baseline to the end of treatment. RESULTS A total of 965 patients were enrolled in the full analysis set and 894 in the safety set in this interim analysis. The average daily dose was 61.7 ± 19.08 mg (mean ± SD) during the treatment. AEs and ADRs were experienced by 101 patients (11.3%) and 78 patients (8.7%), respectively, which were mostly mild. EPS occurred in 25 individuals with a 2.8% incidence, including akathisia in 20 individuals (2.2%). Moreover, 59 patients received drugs for treating EPS during the treatment, with an incidence of 6.6% which dropped to 5.4% at the end of the treatment. The average weight change was 0.20 ± 2.36 kg (P = 0.01687) with 0.8% of patients showing a weight gain of ≥ 7% at week 12 compared with that at the baseline. The mean values of metabolic parameters and the QTc interval at baseline and week 12 were within normal ranges. The mean changes in total BPRS scores were -8.9 ± 9.76 (n = 959), -13.5 ± 12.29 (n = 959), and -16.8 ± 13.97 (n = 959) after 2/4, 6/8, and 12 wk, respectively (P < 0.001 for each visit compared with the baseline) using the last-observation-carried-forward method. CONCLUSION The interim analysis of the PMS of adult patients with schizophrenia demonstrate the safety and effectiveness of lurasidone in the Chinese population. No new safety or efficacy concerns were identified.

27 January 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
MLMengfei Liu
Mengfei Liu
YHYi Huang
Yi Huang
HTHongrui Tian
Hongrui Tian
CGChuanhai Guo
Chuanhai Guo
ZLZhen Liu
Zhen Liu
YKYang Ke
Yang Ke
Background: Esophageal squamous cell carcinoma (ESCC) exhibits a long latency period and has a significant geographic disparity in incidence, which underscores the need for models predicting the long-term absolute risk adaptable to the regional disease burden. Methods: A total of 31,883 participants in a large-scale population-based screening trial (Hua County, China) were enrolled to develop the model. Severe dysplasia and above cases identified at screening or follow-up were defined as the outcome. We calculated the absolute risk in three steps: (i) constructing a relative risk model using logistic regression, (ii) calculating the age-specific baseline hazard, and (iii) adjusting for the competing risk of all-cause death excluding ESCC. Flexible incidence rate parameters were integrated into the model to ensure its relevance across diverse regions worldwide. Results: A total of 295 severe dysplasia and above cases were detected. The relative risk model consisted of old age, male gender, an irregular meal pattern, a preference for hot or hard food, a BMI of less than 22 kg/m2, and ESCC family history. The AUC was 0.753 (95% confidence interval, 0.749–0.757). The averaged 5-and 10-year absolute risk were 0.53% and 1.30% among participants. Based on our model, we developed an online calculator and incorporated flexible incidence rate parameters, demonstrating ideal risk stratification tailored to regions with varying disease burdens (https://pkugenetics.shinyapps.io/escc_risk_prediction/). Conclusions: We developed an absolute risk model to predict individualized long-term risk of ESCC, accounting for the local disease burden. Impact: This model has the potential to mitigate the global burden of ESCC by enabling targeted screening and personalized prevention strategies.

3 April 2025
Verified
Other
Open access
PDF file
MLMengfei Liu
Mengfei Liu
YHYi Huang
Yi Huang
HTHongrui Tian
Hongrui Tian
CGChuanhai Guo
Chuanhai Guo
ZLZhen Liu
Zhen Liu
YKYang Ke
Yang Ke
Table S2 showed the age-specific incidence rate and baseline hazard of Hua County

3 April 2025
Verified
Other
Open access
PDF file
MLMengfei Liu
Mengfei Liu
YHYi Huang
Yi Huang
HTHongrui Tian
Hongrui Tian
CGChuanhai Guo
Chuanhai Guo
ZLZhen Liu
Zhen Liu
YKYang Ke
Yang Ke
Table S3 showed that the all-cause mortality excluding ESCC of Hua County

3 April 2025
Verified
Other
Open access
MLMengfei Liu
Mengfei Liu
YHYi Huang
Yi Huang
HTHongrui Tian
Hongrui Tian
CGChuanhai Guo
Chuanhai Guo
ZLZhen Liu
Zhen Liu
YKYang Ke
Yang Ke
Background:Esophageal squamous cell carcinoma (ESCC) exhibits a long latency period and has a significant geographic disparity in incidence, which underscores the need for models predicting the long-term absolute risk adaptable to the regional disease burden.Methods:A total of 31,883 participants in a large-scale population-based screening trial (Hua County, China) were enrolled to develop the model. Severe dysplasia and above cases identified at screening or follow-up were defined as the outcome. We calculated the absolute risk in three steps: (i) constructing a relative risk model using logistic regression, (ii) calculating the age-specific baseline hazard, and (iii) adjusting for the competing risk of all-cause death excluding ESCC. Flexible incidence rate parameters were integrated into the model to ensure its relevance across diverse regions worldwide.Results:A total of 295 severe dysplasia and above cases were detected. The relative risk model consisted of old age, male gender, an irregular meal pattern, a preference for hot or hard food, a BMI of less than 22 kg/m2, and ESCC family history. The AUC was 0.753 (95% confidence interval, 0.749–0.757). The averaged 5-and 10-year absolute risk were 0.53% and 1.30% among participants. Based on our model, we developed an online calculator and incorporated flexible incidence rate parameters, demonstrating ideal risk stratification tailored to regions with varying disease burdens (https://pkugenetics.shinyapps.io/escc_risk_prediction/).Conclusions:We developed an absolute risk model to predict individualized long-term risk of ESCC, accounting for the local disease burden.Impact:This model has the potential to mitigate the global burden of ESCC by enabling targeted screening and personalized prevention strategies.

3 April 2025
Verified
Other
Open access
PDF file
MLMengfei Liu
Mengfei Liu
YHYi Huang
Yi Huang
HTHongrui Tian
Hongrui Tian
CGChuanhai Guo
Chuanhai Guo
ZLZhen Liu
Zhen Liu
YKYang Ke
Yang Ke
Table S1 showed the crude odds ratios and p value of all the evaluated risk factors for ESCC